Vincere Biosciences
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Vincere Biosciences is redefining what’s possible by targeting one of the most fundamental drivers of mitochondrial dysfunction, which underlies several diseases including Parkinson’s disease (PD). Rather than merely alleviating symptoms, our approach seeks to change the trajectory of disease by restoring mitochondrial function. Our lead program focuses on enhancing mitophagy through selective USP30 inhibition, enabling the clearance of damaged mitochondria. In this manner, we are pursuing first-in-class, disease-modifying oral small brain penetrant small molecules for PD, traditionally considered untreatable.
Our CNS candidate, VB-23, is currently undergoing IND-enabling studies for PD and is expected to be IND-ready mid-2026, with out-licensing as the primary objective. In parallel, we are progressing a peripherally restricted development candidate for cardiorenal and metabolic diseases, expected to reach IND in 2027.
Company HQ City:
Cambridge
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Oral, Selective, CNS-Penetrant, USP30 Inhibitors
CEO
Spring Behrouz, PhD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Sept, 2026
What is your next catalyst (value inflection) update?
IND tox study completion
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}